Yonsei Med J.  2011 Nov;52(6):898-908. 10.3349/ymj.2011.52.6.898.

Hypoglycemia Revisited in the Acute Care Setting

• Tsai SH
• Lin YY
• Hsu CW
• Cheng CS
• Chu DM

• KMID: 1058808
• DOI: http://doi.org/10.3349/ymj.2011.52.6.898

Abstract

Hypoglycemia is a common finding in both daily clinical practice and acute care settings. The causes of severe hypoglycemia (SH) are multi-factorial and the major etiologies are iatrogenic, infectious diseases with sepsis and tumor or autoimmune diseases. With the advent of aggressive lowering of HbA1c values to achieve optimal glycemic control, patients are at increased risk of hypoglycemic episodes. Iatrogenic hypoglycemia can cause recurrent morbidity, sometime irreversible neurologic complications and even death, and further preclude maintenance of euglycemia over a lifetime of diabetes. Recent studies have shown that hypoglycemia is associated with adverse outcomes in many acute illnesses. In addition, hypoglycemia is associated with increased mortality among elderly and non-diabetic hospitalized patients. Clinicians should have high clinical suspicion of subtle symptoms of hypoglycemia and provide prompt treatment. Clinicians should know that hypoglycemia is associated with considerable adverse outcomes in many acute critical illnesses. In order to reduce hypoglycemia-associated morbidity and mortality, timely health education programs and close monitoring should be applied to those diabetic patients presenting to the Emergency Department with SH. ED disposition strategies should be further validated and justified to achieve balance between the benefits of euglycemia and the risks of SH. We discuss relevant issues regarding hypoglycemia in emergency and critical care settings.

Keyword

Hypoglycemia; hyperglycemia; diabetes mellitus; emergency medicine; intensive care unit; anti-diabetic agents; insulin

MeSH Terms

Diabetes Mellitus/drug therapy
Humans
Hypoglycemia/blood/*chemically induced/*complications/epidemiology
Hypoglycemic Agents/adverse effects/therapeutic use
Insulin/adverse effects/therapeutic use

Reference

1. Kotsaftis P, Ntaios G, Savopoulos C, Kiparoglou R, Agapakis D, Baltatzi M, et al. Trend in incidence of cardiovascular risk factors in elderly and over-aged stroke patients between 2003 and 2007 in Greece. Arch Gerontol Geriatr. 2010. 50:e31–e35.

2. Yu PC, Bosnyak Z, Ceriello A. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010. 89:1–9.

3. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008. 358:2545–2559.

4. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med. 1997. 14:919–928.

5. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005. 54:3592–3601.

6. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001. 161:1653–1659.

7. Mitchell E, Medzon R. Introduction to emergency medicine. 2005. Philadelphia: Lippincott Williams & Willkins.

8. Tintinalli JE, Stapczynski JS. Tintinalli's emergency medicine: a comprehensive study guide. 2011. 7th ed. New York: McGraw-Hill.

9. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001. 161:1653–1659.

10. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008. 57:3169–3176.

11. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008. 358:2630–2633.

12. Arabi YM, Tamim HM, Rishu AH. Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. Crit Care Med. 2009. 37:2536–2544.

13. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest. 2010. 137:544–551.

14. Kosiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009. 301:1556–1564.

15. Goyal A, Mehta SR, Díaz R, Gerstein HC, Afzal R, Xavier D, et al. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation. 2009. 120:2429–2437.

16. Ntaios G, Egli M, Faouzi M, Michel P. J-shaped association between serum glucose and functional outcome in acute ischemic stroke. Stroke. 2010. 41:2366–2370.

17. Mannucci E, Monami M, Mannucci M, Chiasserini V, Nicoletti P, Gabbani L, et al. Incidence and prognostic significance of hypoglycemia in hospitalized non-diabetic elderly patients. Aging Clin Exp Res. 2006. 18:446–451.

18. Kagansky N, Levy S, Rimon E, Cojocaru L, Fridman A, Ozer Z, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med. 2003. 163:1825–1829.

19. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation. 2000. 101:2047–2052.

20. Guettier JM, Gorden P. Hypoglycemia. Endocrinol Metab Clin North Am. 2006. 35:753–766. viii–viix.

21. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005. 28:1245–1249.

22. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010. 363:1410–1418.

23. Ichai C, Preiser JC. Société Française d'Anesthésie-Réanimation. Société de Réanimation de langue Française. Experts group. International recommendations for glucose control in adult non diabetic critically ill patients. Crit Care. 2010. 14:R166.

24. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003. 26:1902–1912.

25. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009. 94:709–728.

26. Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2004. 350:2272–2279.

27. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med. 2006. 23:750–756.

28. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications. 2006. 20:402–408.

29. Control Group. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009. 52:2288–2298.

30. ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008. 358:2560–2572.

31. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–986.

32. Warren RE, Frier BM. Hypoglycaemia and cognitive function. Diabetes Obes Metab. 2005. 7:493–503.

33. Cryer PE. Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness. Endocrinol Metab Clin North Am. 1999. 28:495–500. v–vi.

34. Thomson FJ, Masson EA, Leeming JT, Boulton AJ. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing. 1991. 20:404–406.

35. Bell DS. Nocturnal hypoglycaemia presenting as somnambulism. Diabetologia. 2010. 53:2066–2067.

36. Redelmeier DA, Kenshole AB, Ray JG. Motor vehicle crashes in diabetic patients with tight glycemic control: a population-based case control analysis. PLoS Med. 2009. 6:e1000192.

37. Lin YY, Hsu CW, Sheu WH, Chu SJ, Wu CP, Tsai SH. Risk factors for recurrent hypoglycemia in hospitalized diabetic patients admitted for severe hypoglycemia. Yonsei Med J. 2010. 51:367–374.

38. MacDonald MJ. Postexercise late-onset hypoglycemia in insulin-dependent diabetic patients. Diabetes Care. 1987. 10:584–588.

39. Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, et al. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr. 2005. 147:528–534.

40. Huang Z, Sjöholm A. Ethanol acutely stimulates islet blood flow, amplifies insulin secretion, and induces hypoglycemia via nitric oxide and vagally mediated mechanisms. Endocrinology. 2008. 149:232–236.

41. Sorlini M, Benini F, Cravarezza P, Romanelli G. Hypoglycemia, an atypical early sign of hepatocellular carcinoma. J Gastrointest Cancer. 2010. 41:209–211.

42. Lau CI, Wang HC, Hsu WC. Hypoglycemic encephalopathy as the initial presentation of hepatic tumor: a case report. Neurologist. 2010. 16:206–207.

43. Keller BC, Nussensveig D, Dowell JE. Diffuse large B-cell lymphoma in a hepatitis C virus-infected patient presenting with lactic acidosis and hypoglycemia. Am J Med Sci. 2010. 339:202–204.

44. Diaz J, Antoine J, Azad N. A case of hypoglycemia, lactic acidosis, and hematologic malignancy. Endocr Pract. 2010. 16:241–243.

45. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010. 12:772–779.

46. Hamnvik OP, McMahon GT. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med. 2009. 76:234–243.

47. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. 352:837–853.

48. Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet. 1996. 31:111–119.

49. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998. 32:1044–1052.

50. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol. 2003. 59:91–97.

51. Neumiller JJ, Setter SM, Gates BJ, Sonnett TE, Dobbins EK, Campbell K. Pharmacological management of glycemic control in the geriatric patient with type 2 diabetes mellitus. Consult Pharm. 2009. 24:45–63.

52. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997. 157:1681–1686.

53. Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf. 2010. 9:675–681.

54. Barnett AH. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Curr Med Res Opin. 2010. 26:1333–1342.

55. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003. 111:405–414.

56. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006. 355:2427–2443.

57. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008. 116:6–13.

58. Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract. 2010. 64:1121–1129.

59. Raptis SA, Dimitriadis GD. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes. 2001. 109:Suppl 2. S265–S287.

60. Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, et al. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009. 94:741–745.

61. Kelesidis T, Canseco E. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect. Am J Med. 2010. 123:e5–e6.

62. Kelesidis T, Canseco E. Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely used antibiotic. Am J Med. 2009. 122:e3–e4.

63. Soldevila Madorell B, Joaquim Ortiz C, Colomé Tatché E, Flores Meneses L. [Tonic water as cause of severe hypoglycemia in non-diabetic subject]. Med Clin (Barc). 2006. 127:639.

64. Negishi M, Shimomura K, Proks P, Mori M, Shimomura Y. Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009. 26:76–78.

65. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol. 2004. 497:111–117.

66. Maeda N, Tamagawa T, Niki I, Miura H, Ozawa K, Watanabe G, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol. 1996. 117:372–376.

67. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther. 2010. 88:214–222.

68. Roustit M, Blondel E, Villier C, Fonrose X, Mallaret MP. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Ann Pharmacother. 2010. 44:764–767.

69. Lin YY, Hsu CW, Chu SJ, Tsai SH. Another dangerous combination for hypoglycemic coma: concurrent use of sibutramine and lorazepam. QJM. 2008. 101:243–245.

70. Hatzitolios A, Savopoulos C, Ntaios G, Papadidaskalou F, Dimitrakoudi E, Kosmidou M, et al. Stroke and conditions that mimic it: a protocol secures a safe early recognition. Hippokratia. 2008. 12:98–102.

71. Adams H, Adams R, Del Zoppo G, Goldstein LB. Stroke Council of the American Heart Association. American Stroke Association. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005. 36:916–923.

72. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005. 112:IV1–IV203.

73. Whiticar R, Smith S, Wathen C. Hypoglycaemia--one of the 'H's or not! Resuscitation. 2007. 74:573–574.

74. Tintinalli JE, Kelen GD, Stapczynski JS. Emergency medicine: a comprehensive study guide. 2004. 6th ed. New York: McGraw-Hill, Medical Pub. Division.

75. Sinert R, Su M, Secko M, Zehtabchi S. The utility of routine laboratory testing in hypoglycaemic emergency department patients. Emerg Med J. 2009. 26:28–31.

76. Socransky SJ, Pirrallo RG, Rubin JM. Out-of-hospital treatment of hypoglycemia: refusal of transport and patient outcome. Acad Emerg Med. 1998. 5:1080–1085.

77. Carter AJ, Keane PS, Dreyer JF. Transport refusal by hypoglycemic patients after on-scene intravenous dextrose. Acad Emerg Med. 2002. 9:855–857.

78. Mechem CC, Kreshak AA, Barger J, Shofer FS. The short-term outcome of hypoglycemic diabetic patients who refuse ambulance transport after out-of-hospital therapy. Acad Emerg Med. 1998. 5:768–772.

79. Lin YY, Hsu CW, Sheu WH, Chu SJ, Wu CP, Tsai SH. Use of therapeutic responses to glucose replacement to predict glucose patterns in diabetic patients presenting with severe hypoglycaemia. Int J Clin Pract. 2009. 63:1161–1166.

80. Lu M, Inboriboon PC. Lantus insulin overdose: A case report. J Emerg Med. 2010.

81. Thewjitcharoen Y, Lekpittaya N, Himathongkam T. Attempted suicide by massive insulin injection: a case report and review of the literature. J Med Assoc Thai. 2008. 91:1920–1924.

82. Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993. 76:752–756.

83. Lheureux PE, Zahir S, Penaloza A, Gris M. Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide. Crit Care. 2005. 9:543–549.

84. Vallurupalli S. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Ann Pharmacother. 2010. 44:387–390.

85. Gonzalez RR, Zweig S, Rao J, Block R, Greene LW. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure. Endocr Pract. 2007. 13:417–423.

86. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009. 37:3001–3009.

87. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010. 33:1529–1535.

88. Infusino F, Pitocco D, Zaccardi F, Scalone G, Coviello I, Nerla R, et al. Low glucose blood levels are associated with abnormal cardiac sympatho-vagal balance in type 2 diabetic patients with coronary artery disease. Eur Rev Med Pharmacol Sci. 2010. 14:203–207.

89. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia. 2009. 52:42–45.

90. Feldman-Billard S, Massin P, Meas T, Guillausseau PJ, Héron E. Hypoglycemia-induced blood pressure elevation in patients with diabetes. Arch Intern Med. 2010. 170:829–831.

91. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002. 360:1903–1913.

92. Ohwada R, Hotta M, Kimura H, Takagi S, Matsuda N, Nomura K, et al. Ampulla cardiomyopathy after hypoglycemia in three young female patients with anorexia nervosa. Intern Med. 2005. 44:228–233.

93. Ono T, Kasaoka S, Fujita M, Yamashita S, Kumagai K, Kaneda K, et al. Complete recovery from severe myocardial dysfunction in a patient with anorexia nervosa. J Cardiol. 2009. 54:480–484.

94. Bergner DW, Goldberger JJ. Diabetes mellitus and sudden cardiac death: what are the data? Cardiol J. 2010. 17:117–129.

95. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999. 16:466–471.

96. Gamble JM, Eurich DT, Marrie TJ, Majumdar SR. Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia. Am J Med. 2010. 123:556.e11–556.e16.

97. Singanayagam A, Chalmers JD, Hill AT. Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia. Eur Respir J. 2009. 34:932–939.

98. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Taori G, et al. Hypoglycemia and outcome in critically ill patients. Mayo Clin Proc. 2010. 85:217–224.

99. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008. 36:296–327.

100. Margulescu AD, Sisu RC, Cinteza M, Vinereanu D. Noncardiogenic acute pulmonary edema due to severe hypoglycemia--an old but ignored cause. Am J Emerg Med. 2008. 26:839.e3–839.e6.

101. Mishriki YY. Hypoglycemia-induced neurogenic-type pulmonary edema: an underrecognized association. Endocr Pract. 2004. 10:429–431.

102. Uchida D, Ohigashi S, Hikita S, Kitamura N, Motoyoshi M, Tatsuno I. Acute pulmonary edema caused by hypoglycemia due to insulin overdose. Intern Med. 2004. 43:1056–1059.

103. Sontineni SP, Lee JM, Porter J. Hypoglycemia-induced pontine infarction in a diabetic male with basilar artery stenosis: insight into the mechanisms of hypoglycemic stroke. Cerebrovasc Dis. 2008. 25:281–282.

104. Shirayama H, Ohshiro Y, Kinjo Y, Taira S, Teruya I, Nakachi K, et al. Acute brain injury in hypoglycaemia-induced hemiplegia. Diabet Med. 2004. 21:623–624.

105. Jarjour IT, Ryan CM, Becker DJ. Regional cerebral blood flow during hypoglycaemia in children with IDDM. Diabetologia. 1995. 38:1090–1095.

106. Kim JH, Roh JH, Koh SB. Reversible injury of internal capsule and splenium in a patient with transient hypoglycemic hemiparesis. Cerebrovasc Dis. 2006. 22:282–283.

107. Ma JH, Kim YJ, Yoo WJ, Ihn YK, Kim JY, Song HH, et al. MR imaging of hypoglycemic encephalopathy: lesion distribution and prognosis prediction by diffusion-weighted imaging. Neuroradiology. 2009. 51:641–649.

108. Auer RN. Hypoglycemic brain damage. Metab Brain Dis. 2004. 19:169–175.

109. Purucker E, Nguyen HN, Lammert F, Koch A, Matern S. Central pontine myelinolysis and myocardial infarction following severe hypoglycemia. Intensive Care Med. 2000. 26:1406–1407.

110. de Courten-Myers GM, Xi G, Hwang JH, Dunn RS, Mills AS, Holland SK, et al. Hypoglycemic brain injury: potentiation from respiratory depression and injury aggravation from hyperglycemic treatment overshoots. J Cereb Blood Flow Metab. 2000. 20:82–92.

111. Michel P, Odier C, Rutgers M, Reichhart M, Maeder P, Meuli R, et al. The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. Stroke. 2010. 41:2491–2498.

112. Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2010. 87:64–68.

113. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008. 25:501–504.

114. Izumi K, Kondo S, Okada T. A case of atypical thyroid storm with hypoglycemia and lactic acidosis. Endocr J. 2009. 56:747–752.

115. Homma M, Shimizu S, Ogata M, Yamada Y, Saito T, Yamamoto T. Hypoglycemic coma masquerading thyrotoxic storm. Intern Med. 1999. 38:871–874.

116. Moghetti P, Castello R, Tosi F, Zenti MG, Magnani C, Bolner A. Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects. J Clin Endocrinol Metab. 1994. 78:169–173.

117. Nishizawa S, Nakamura T, Hamaoka T, Matsumuro A, Sawada T, Matsubara H. Lethal arrhythmia and corticosteroid insufficiency. Am J Emerg Med. 2009. 27:1167.e1–1167.e3.

118. Heller SR, Robinson RT. Hypoglycaemia and associated hypokalaemia in diabetes: mechanisms, clinical implications and prevention. Diabetes Obes Metab. 2000. 2:75–82.

119. Paolisso G, Sgambato S, Passariello N, Giugliano D, Scheen A, D'Onofrio F, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia. 1986. 29:644–647.

120. Tofade TS, Liles EA. Intentional overdose with insulin glargine and insulin aspart. Pharmacotherapy. 2004. 24:1412–1418.

121. Matsumura M, Nakashima A, Tofuku Y. Electrolyte disorders following massive insulin overdose in a patient with type 2 diabetes. Intern Med. 2000. 39:55–57.

122. Jolliet P, Leverve X, Pichard C. Acute hepatic steatosis complicating massive insulin overdose and excessive glucose administration. Intensive Care Med. 2001. 27:313–316.

123. Tsujimoto T, Takano M, Nishiofuku M, Yoshiji H, Matsumura Y, Kuriyama S, et al. .Rapid onset of glycogen storage hepatomegaly in a type-2 diabetic patient after a massive dose of long-acting insulin and large doses of glucose. Intern Med. 2006. 45:469–473.